VIDEO: Highlights in endometrial cancer from ESMO Congress
Click Here to Manage Email Alerts
In this video, Elizabeth Lee, MD, of the Dana-Farber Cancer Institute, highlighted promising endometrial cancer presentations from ESMO Congress.
She discussed a phase 1/phase 2 study of rinatabart sesutecan, or Rina-S, in patients with ovarian or endometrial cancer. Lee noted that within the dose escalation portion of the study, the endometrial and ovarian cancer objective response rate of 30.8% was “overall quite encouraging.”
“I think the takeaway there is that (FRalpha)-directed [antibody-drug conjugates (ADCs)], including Rina-S, does potentially have a role in endometrial cancers, and that we really shouldn't be thinking about FRalpha ADCs as really only within the realm of ovarian cancers. That's not the case. So, it's been quite exciting to see this data and to be able to present it at ESMO,” Lee said.
Lee also discussed a study on STX-478, a mutant-selective PI3Ka inhibitor, in advanced patients with solid tumors, including endometrial cancer.
“There needs to be more data, a larger population size studied for endometrial cancer to really get a better sense, but I think it is very intriguing, it's encouraging, and really is as suggestive of a role for these newer generations of PI3Ka inhibitors that can be tolerable for patients,” Lee told Healio.
Lee also mentioned an important study presented at ESMO Congress 2024 on sacituzumab tirumotecan, or sac-TMT. The phase 2 study showed promise in safety and efficacy in patients with heavily pretreated advanced endometrial cancer and ovarian cancer.
“This also speaks to a larger question of what we do for the treatment of [patients with endometrial cancer] who may be expressing multiple different target antigens, and how we sequence our therapies,” she said.
References:
- Lee EK, et al. Abstract 719MO. Presented at: ESMO Annual Meeting; September 13-17, 2024; Barcelona, Spain.
- Montero AJ, et al. Abstract LBA27. Presented at: ESMO Annual Meeting; September 13-17, 2024; Barcelona, Spain.
- Wang D, et al. Abstract 715MO. Presented at: ESMO Annual Meeting; September 13-17, 2024; Barcelona, Spain.
Collapse
Read more about
Click Here to Manage Email Alerts